🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInsurance & AccessVA healthcare GLP-1 access — September 2026 Page 5

VA healthcare GLP-1 access — September 2026

mike_mod Wed, Feb 18, 2026 at 3:51 PM 23 replies 1,068 viewsPage 5 of 5
tammy_FL
Member
234
890
Nov 2024
Tampa, FL
Mar 14, 2026 at 3:38 AM#21
stefan_berlin said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Agreed on the substance. I would put less weight on the timescale, because two months of anything is not enough to distinguish a trend from a wobble.

Correct me if the detail matters more than I have assumed.

Last edited: Mar 14, 2026 at 9:38 AM
13 11Dr.LipidDallas, alex_tucson, kevin_tulsa and 10 others
Reply Quote Save Share Report
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
Mar 22, 2026 at 2:42 PM#22
stefan_berlin said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

That reframing is the part I needed. I will report back once I have actually tried it.

14 12Dr.NateNeph, PharmD_Rodriguez, julia.endo and 11 others
Reply Quote Save Share Report
sophie_paris
Member
212
890
Nov 2024
Paris, FR
Mar 31, 2026 at 1:41 AM#23

Adding the clinical framing, because it changes how the question reads. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

Last edited: Mar 31, 2026 at 6:41 AM
15 13MariaRD, AussieAnna, BethLabQueen and 12 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Apr 8, 2026 at 12:35 PM#24
sophie_paris said:
The useful move here is to separate what is established from what is widely repeated.

This is my experience too, for whatever a second data point is worth. I had assumed I was the exception until I read this.

16 14sophie_paris, mel_PDX, Dr.AddMedPHL and 13 others
Reply Quote Save Share Report
LarryQC_SD
Senior Member
2,123
9,876
Jan 2024
San Diego, CA
Apr 16, 2026 at 11:24 PM#25
sophie_paris said:
The useful move here is to separate what is established from what is widely repeated.

There is a second half to this that has not been said yet. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.

Last edited: Apr 17, 2026 at 12:24 AM
17 15dan_philly, MeganSA_TX, LarryQC_SD and 14 others
Reply Quote Save Share Report
1345

Similar Threads

Prior authorization success: step-by-step guide with templates5 replies
Cigna now covering Zepbound — how I got approved13 replies
Appeal letter template — denied PA for GLP-1 medications4 replies
Mounjaro savings card — manufacturer program changes 202610 replies
Medicare Part D GLP-1 coverage — what's covered in 202610 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register